학술논문

Complete remission of aggressive Epstein–Barr virus‐positive diffuse large B‐cell lymphoma following withdrawal of tacrolimus and low‐dose anticancer drugs
Document Type
Report
Source
ejHaem. November 2023, Vol. 4 Issue 4, p1160, 4 p.
Subject
Drug therapy
Health aspects
Systemic lupus erythematosus -- Drug therapy
Non-Hodgkin lymphomas -- Drug therapy
Tacrolimus -- Health aspects
Rheumatoid factor -- Health aspects
Chemotherapy -- Health aspects
Methotrexate -- Health aspects
Arthritis -- Drug therapy
Non-Hodgkin's lymphomas -- Drug therapy
Cancer -- Chemotherapy
Language
English
Abstract
INTRODUCTION Lymphoproliferative disorders (LPDs) that develop during the use of immunosuppressive agents for autoimmune diseases are classified by the World Health Organization as other iatrogenic immunodeficiency‐associated LPDs (OIIA‐LPDs), and methotrexate [...]
: A 66‐year‐old woman who had received tacrolimus for more than 11 years was admitted with high fever, generalized lymphadenopathy, and persistent gastrointestinal bleeding. Histopathological evaluation of the lymph nodes and colonic mucosa confirmed the diagnosis of Epstein–Barr virus‐positive diffuse large B‐cell lymphoma. After discontinuation of tacrolimus, the lymphoma did not improve, and low‐dose chemotherapy was introduced, which resulted in a recovery of lymphocyte counts and induction of complete remission. Low‐dose anticancer treatments that suppress tumor growth while awaiting normal lymphocyte recovery for several weeks may be a useful therapeutic option even for aggressive lymphomas that develop during immunosuppressant therapy.